Tripling the weekly dose of semaglutide (Ozempic, Wegovy) resulted in greater weight loss compared with placebo in adults ...

"For them to work effectively, they need to be taken long term," cautioned epidemiologisy professor Reimar W. Thomsen.

A microsimulation model was used to evaluate the cost-effectiveness of two glucagon-like peptide-1 receptor agonists (GLP1RAs ...

A higher weekly dose of semaglutide (7.2 mg) can significantly improve weight loss and related health outcomes in adults ...

Oral semaglutide (Rybelsus®) is now the first and only oral GLP-1 RA approved for type 2 diabetes, with proven cardiovascular ...

Half of people who start taking the GLP-1 weight-loss drugs Ozempic and Wegovy drop it within a year, Danish researchers ...

Tirzepatide is more cost-effective than semaglutide for knee osteoarthritis and obesity, optimizing resources for patients not seeking surgical options, which remain cost-effective for those eligible.

In a real-world population of patients with obesity and atherosclerotic CVD but no diabetes, semaglutide conferred a lower ...

In The Lancet Diabetes & Endocrinology, the STEP-UP T2D and STEP-UP trial groups present new findings on the efficacy and safety of higher-dose semaglutide (7·2 mg once weekly) in individuals with ...

A study published in The Lancet Diabetes & Endocrinology journal, suggest that a higher dose of semaglutide offers a ...

Higher semaglutide dose of 7.2 mg was associated with superior weight loss and comparable safety outcomes among patients with obesity.

New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September ...